A Phase I Study of Cetuximab and Lapatinib In Patients with Advanced Solid Tumor Malignancies

BACKGROUND: Acquired resistance to anti-EGFR therapy may be due to EGFR-ErbB2 heterodimerization and pathway reactivation. In pre-clinical studies. inhibiting ErbB2 blocked this resistance mechanism and re-sensitized cells to anti-EGFR therapy. Cetuximab targets the EGFR receptor, whereas lapatinib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Deeken, John F., Wang, Hongkun, Subramaniam, Deepa, He, Aiwu Ruth, Hwang, Jimmy, Marshall, John L., Urso, Christina E., Wang, Yiru, Ramos, Corinne, Steadman, Kenneth, Pishvaian, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424139/
https://ncbi.nlm.nih.gov/pubmed/25641763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29224
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados